Adverum Biotechnologies (ADVM) Company Report

On December 4, 2025, Adverum Biotechnologies, Inc. announced positive two-year long-term follow-up data from its LUNA Phase 2 clinical trial of Ixo-vec in patients with wet age-related macular degeneration (AMD).
Ixo-vec demonstrated a consistent ~90% reduction in mean annualized anti-VEGF injection burden over two years, with rates dropping from approximately 10 injections in the prior year to 1.1 in the 6E10 group and 0.9 in the 2E11 group.
The therapy showed sustained anatomic control and best corrected visual acuity through two years and was well tolerated, with no new inflammation observed after week 30 in participants receiving the 6E10 dose and local prophylaxis.
The company anticipates completing full enrollment for its pivotal Phase 3 ARTEMIS trial on December 5, 2025, having enrolled 110% of the original target. Topline data for this trial is anticipated in Q1 2027.

Dec 4, 2025, 9:36 PM

Eli Lilly and Company to Acquire Adverum Biotechnologies

ADVM

M&A

Takeover Bid

New Projects/Investments

Eli Lilly and Company announced a definitive agreement to acquire Adverum Biotechnologies, Inc..
The acquisition offers $3.56 per share in cash at closing, plus one non-transferrable contingent value right (CVR).
The CVR could provide up to an additional $8.91 per CVR upon the achievement of two milestones, resulting in a total potential per share consideration of up to $12.47.
The CVR milestones include U.S. approval of Ixo-vec (up to $1.78 per CVR) and annual worldwide net sales of Ixo-vec exceeding $1.0 billion (up to $7.13 per CVR).
Ixo-vec, Adverum's lead program, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration (wAMD). The transaction is expected to close in the fourth quarter of 2025.

Oct 24, 2025, 1:19 PM

Adverum Biotechnologies Completes Screening for Pivotal Phase 3 ARTEMIS Trial, Accelerates Timelines

ADVM

New Projects/Investments

Guidance Update

Adverum Biotechnologies, Inc. has completed screening for its pivotal Phase 3 ARTEMIS trial, which evaluates Ixo-vec for wet age-related macular degeneration (wet AMD).
The completion of screening occurred ahead of expectations.
Full enrollment for the ARTEMIS trial is now anticipated in Q4 2025, an acceleration from the previous expectation of Q1 2026.
The topline data readout for the ARTEMIS trial has been accelerated to Q1 2027.

Sep 22, 2025, 12:11 PM

Adverum Biotechnologies Provides Update on Wet AMD Gene Therapy Program

ADVM

New Projects/Investments

Revenue Acceleration/Inflection

Adverum Biotechnologies is advancing its intravitreal gene therapy, Ixo-vec, for wet AMD, which aims to provide long-term aflibercept expression after a single injection.
The company is preparing to initiate a Phase III trial (Artemis) for Ixo-vec, enrolling 284 patients to compare it against Eylea, with a goal for the broadest label.
Ixo-vec has demonstrated a strong safety profile with zero inflammation at week 52 in the Luna trial for the dose moving to Phase III, and no vision-threatening safety events.
The wet AMD market is valued at approximately $9 billion and is projected to grow to $12-$15 billion, with Adverum anticipating a multi-billion dollar opportunity even with a small market capture.

Feb 11, 2025, 9:40 PM

Adverum Biotechnologies Prepares for Phase III Trial of Wet AMD Gene Therapy Exovec

ADVM

New Projects/Investments

Product Launch

Adverum Biotechnologies is preparing to initiate its Phase III Artemis trial for Exovec, an intravitreal gene therapy for wet AMD, which will enroll 284 patients and compare it to Eylea every eight weeks.
Clinical data for the Phase III dose of Exovec showed 54% of patients were injection-free at year one and 75% had less than one injection in the Luna trial, with a safety profile indicating no vision-threatening events and no patients with 1+ inflammation at 52 weeks.
The wet AMD market is valued at approximately $9 billion and is projected to grow to $12-$15 billion, with Adverum estimating that capturing just 3% of this market in the first year could yield a billion-dollar plus product.